HK1180727A1 - Tests to predict responsiveness of cancer patients to chemotherapy treatment options - Google Patents

Tests to predict responsiveness of cancer patients to chemotherapy treatment options

Info

Publication number
HK1180727A1
HK1180727A1 HK13107812.6A HK13107812A HK1180727A1 HK 1180727 A1 HK1180727 A1 HK 1180727A1 HK 13107812 A HK13107812 A HK 13107812A HK 1180727 A1 HK1180727 A1 HK 1180727A1
Authority
HK
Hong Kong
Prior art keywords
tests
cancer patients
treatment options
chemotherapy treatment
predict responsiveness
Prior art date
Application number
HK13107812.6A
Other languages
English (en)
Chinese (zh)
Inventor
Steve Shak
Joffre Baker
Carl Yoshizawa
Joseph Sparano
Robert Gray
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of HK1180727A1 publication Critical patent/HK1180727A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK13107812.6A 2008-05-12 2011-08-29 Tests to predict responsiveness of cancer patients to chemotherapy treatment options HK1180727A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5257308P 2008-05-12 2008-05-12
US5718208P 2008-05-29 2008-05-29

Publications (1)

Publication Number Publication Date
HK1180727A1 true HK1180727A1 (en) 2013-10-25

Family

ID=41319028

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11109113.0A HK1154910A1 (en) 2008-05-12 2011-08-29 Tests to predict responsiveness of cancer patients to chemotherapy treatment options
HK13107812.6A HK1180727A1 (en) 2008-05-12 2011-08-29 Tests to predict responsiveness of cancer patients to chemotherapy treatment options

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK11109113.0A HK1154910A1 (en) 2008-05-12 2011-08-29 Tests to predict responsiveness of cancer patients to chemotherapy treatment options

Country Status (7)

Country Link
US (1) US20090311702A1 (xx)
EP (5) EP2641977B1 (xx)
CA (1) CA2723972A1 (xx)
DK (2) DK2294215T3 (xx)
ES (2) ES2403220T3 (xx)
HK (2) HK1154910A1 (xx)
WO (1) WO2009140304A1 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2799555B1 (en) * 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
WO2005100606A2 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2006052862A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US8980564B2 (en) 2009-11-20 2015-03-17 The Governors Of The University Of Alberta Predictive markers for taxane responsiveness and methods of use thereof
US20130005597A1 (en) * 2009-12-18 2013-01-03 Rathmell W Kimryn Methods and compositions for analysis of clear cell renal cell carcinoma (ccrcc)
US20130011393A1 (en) * 2010-01-12 2013-01-10 Johnathan Mark Lancaster Bad pathway gene signature
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
US20120053253A1 (en) 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
WO2012097276A2 (en) * 2011-01-13 2012-07-19 Expression Pathology, Inc. Bcl-2-like protein 11 srm/mrm assay
WO2012145575A2 (en) 2011-04-21 2012-10-26 Children's Hospital Medical Center Therapy for leukemia
US10342767B2 (en) 2011-04-21 2019-07-09 Children's Hospital Medical Center Therapy for kinase-dependent malignancies
CN102312002A (zh) * 2011-09-20 2012-01-11 李艳 一种快速检测BRCA1基因mRNA表达量的试剂盒
WO2013130465A2 (en) * 2012-02-27 2013-09-06 Genomic Health, Inc. Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs
WO2013170174A1 (en) * 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
CN102965433A (zh) * 2012-09-29 2013-03-13 李艳 一种检测M BCR融合基因mRNA表达量的试剂盒
EP2920322B1 (en) 2012-11-16 2023-01-11 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2014092572A1 (en) * 2012-12-12 2014-06-19 Universiteit Leiden Improved methods for cancer treatment with a genotoxic agent
CA2912547A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
CA2944401A1 (en) * 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20170079979A1 (en) * 2014-06-02 2017-03-23 Children's Hospital Medical Center Therapy for solid tumors
GB201501930D0 (en) * 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
US11136583B2 (en) 2017-01-10 2021-10-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2019217581A2 (en) * 2018-05-11 2019-11-14 Baylor College Of Medicine Mutl loss predicts sensitivity to cdk4/6 inhibitors in cancer
US20210317535A1 (en) * 2018-08-29 2021-10-14 The Regents Of The University Of Michigan Methods of determining treatment consisting of radiation therapy and/or alkylating chemotherapy in patients suffering from cancer
CN109439755A (zh) * 2018-11-30 2019-03-08 广东腾飞基因科技股份有限公司 一种用于检测乳腺癌相关基因表达水平的试剂盒

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627733B2 (en) * 1993-06-14 2003-09-30 Jeffrey D. Johnson Receptor tyrosine kinase with a discoidin-type binding domain
JP2000038909A (ja) 1998-07-22 2000-02-08 Mitsubishi Electric Corp バルブタイミング可変装置
WO2002033520A2 (en) 2000-10-18 2002-04-25 Genomic Health, Inc. Genomic profile information systems and methods
EP2799555B1 (en) 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
JP2007507222A (ja) * 2003-05-28 2007-03-29 ゲノミック ヘルス， インコーポレイテッド 化学療法に対する応答を予測するための遺伝子発現マーカー
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
CA2531967C (en) 2003-07-10 2013-07-16 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20050095634A1 (en) 2003-10-16 2005-05-05 Genomic Health Inc. qRT-PCR assay system for gene expression profiling
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
WO2005100606A2 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
WO2006052862A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CA2613290A1 (en) * 2005-05-27 2007-05-24 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
CA2611728A1 (en) * 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007028146A2 (en) * 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
WO2007085497A2 (en) * 2006-01-30 2007-08-02 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US20090125247A1 (en) * 2007-08-16 2009-05-14 Joffre Baker Gene expression markers of recurrence risk in cancer patients after chemotherapy

Also Published As

Publication number Publication date
EP2641978A1 (en) 2013-09-25
CA2723972A1 (en) 2009-11-19
ES2482692T3 (es) 2014-08-04
EP2641977B1 (en) 2014-09-03
HK1154910A1 (en) 2012-05-04
EP2294215A4 (en) 2011-06-29
EP2641977A1 (en) 2013-09-25
DK2294215T3 (da) 2013-04-22
EP2568053A1 (en) 2013-03-13
EP2294215B1 (en) 2013-01-16
EP2294215A1 (en) 2011-03-16
DK2568053T3 (da) 2014-07-21
WO2009140304A1 (en) 2009-11-19
ES2403220T3 (es) 2013-05-16
US20090311702A1 (en) 2009-12-17
EP2607497A1 (en) 2013-06-26
EP2568053B1 (en) 2014-04-16
EP2607497B1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
HK1154910A1 (en) Tests to predict responsiveness of cancer patients to chemotherapy treatment options
IL276487B (en) Methods for predicting clinical outcome of cancer
HK1178602A1 (en) Methods for predicting response of triple-negative breast cancer to therapy
IL218575A0 (en) Treatment of cancer
EP2512375A4 (en) EXPANSION DEVICE FOR TREATING VASCULAR PASSAGE PATHWAYS
IL229878A (en) Cancer Treatment Compounds
EP2558599A4 (en) METHODS OF ASSESSING ANTICANCER THERAPY RESPONSE
IL217291A0 (en) Exosome based treatment of cancer
DK3130923T3 (da) Terapeutiske fremgangsmåder i forbindelse med cancerstamceller
SG10201508495VA (en) Combination treatment of cancer
ZA201300218B (en) Treatment of blood cancer
EP2461814A4 (en) PROSTATE CANCER TREATMENT
EP2385114A4 (en) CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY
EP2652156A4 (en) METHOD FOR DETECTING RESISTANCE TO ANTICANCER THERAPY
PL388252A1 (pl) Terapia skojarzona raka jelita grubego
GB0916686D0 (en) Treatment of cancer
EP2294224A4 (en) METHOD FOR PREDICTING THE TUMOR REACTION TO CHEMOTHERAPY AND FOR SELECTING A CARE TREATMENT
IL215199A0 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
EP2214485A4 (en) METHOD FOR THE TREATMENT OF CANCER
GB0712956D0 (en) Therapeutic uses of cannabinoids
GB0921757D0 (en) Treatment of cancer
GB0906490D0 (en) Use of tetanolic for treatment of breast cancer
IL223237A0 (en) Diagnosis of cancer
GB201017354D0 (en) Treatment of cancer
GB0712513D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180512